Zydus Cadila Gets Warning Letter
Addresses FDA Warning Over Moraiya Plant And Commits To Respond
Executive Summary
Zydus Cadila has received a warning letter from the FDA for its Moraiya facility. The company has insisted that it will not affect the existing business in the US where it has filed over 330 ANDAs.
You may also be interested in...
Zydus Ready For Moraiya Reinspection In June
Zydus says its Moraiya plant should be ready for re-inspection at the end of June 2020, following a recent FDA warning letter. Meanwhile, as returns from levorphanol fall on the back of increased competition, the firm has written down investment by $37.5m causing Q2 profits to slump 74%. Post successful Phase II trials in the US for NASH and NAFLD indications, its hopes are now pinned on saroglitazar magnesium.
FDA Holds Zydus Cadila Responsible For ‘Repeat Violations’
The FDA has published details of a warning letter summarizing significant violations of cGMP regulations to Zydus Cadila. The agency called the company’s prior response “insufficient.”
Zydus Cadila’s New Injectables Plant Could Help Blunt US Drug Shortages
Site switch also could trigger ANDA approvals sidelined as Moraiya plant recovers from US FDA warning letter.